Hepatitis B reactivation after chemoimmunotherapy: screen before treatment

Lancet. 2021 Feb 6;397(10273):510. doi: 10.1016/S0140-6736(21)00210-5.

Authors

Jessica P Hwang¹, Alessandra Ferrajoli², Anna S Lok³

Affiliations

¹ Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA. Electronic address: aslok@umich.edu.

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Alanine Transaminase / blood
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antiviral Agents / administration & dosage
Guanine / administration & dosage
Guanine / analogs & derivatives
Hepatitis B / diagnosis*
Hepatitis B / drug therapy
Hepatitis B Surface Antigens / blood
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Recurrence
Rituximab / administration & dosage
Rituximab / adverse effects*
Virus Activation / drug effects*

Substances

Antiviral Agents
Hepatitis B Surface Antigens
Rituximab
entecavir
Guanine
Alanine Transaminase

Grants and funding